Search

Your search keyword '"Keren L. Appel"' showing total 11 results
Start Over Author "Keren L. Appel"
11 results on '"Keren L. Appel"'

1. Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3β-mediated restriction of epithelial IL-33

Author

Michael A. Schumacher, Jonathan J. Hsieh, Cambrian Y. Liu, Keren L. Appel, Amanda Waddell, Dana Almohazey, Kay Katada, Jessica K. Bernard, Edie B. Bucar, Safina Gadeock, Kathryn M. Maselli, M. Kay Washington, Tracy C. Grikscheit, David Warburton, Michael J. Rosen, and Mark R. Frey

Subjects
Science
Abstract

Dynamic regulation of colonic secretory cell numbers is a critical component of the response to intestinal injury and inflammation. Here, the authors show that loss of the intracellular signalling regulator Sprouty2 in the intestinal epithelial cells is a protective response to injury that leads to increased secretory cell numbers, thus limiting colitis severity.

Published
2021
Full Text
View/download PDF

2. Web-Based Video Education to Improve Uptake of Influenza Vaccination and Other Preventive Health Recommendations in Adults With Inflammatory Bowel Disease: Randomized Controlled Trial of Project PREVENT

Author

Millie D Long, Welmoed K van Deen, Laura Weisbein, Carine Khalil, Keren L Appel, Xian Zhang, Wenli Chen, Lori Zubrod, Robbie Maris, Afsoon Ghafari, Taylor Dupuy, Christina Y Ha, Brennan M R Spiegel, Christopher V Almario, and Gil Y Melmed

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundPatients with inflammatory bowel disease (IBD) are at increased risk of infections, bone fractures, and skin cancers. ObjectiveWe developed preventive health videos using a patient-centered approach and tested their impact on preventive health uptake. MethodsFive animated videos explaining preventive health recommendations in IBD were iteratively developed with patient-centered focus groups and interviews. A randomized controlled trial was then conducted in a web-based IBD cohort to test the impact of video- versus text-based educational interventions. The primary outcome was receipt of the influenza vaccine. Secondary outcomes included intention to receive other preventive health services. ResultsFive animated videos were developed with patient input. A total of 1056 patients with IBD were then randomized to receive the video (n=511) or text-only (n=545) interventions; 55% (281/511) of the video group and 57% (311/545) of the text-only group had received their influenza vaccine in the prior year. Immediately after the intervention, 73% (502/683) of patients reported their intention to receive the vaccine, with no difference by the type of intervention (75%, 231/307, for the video group and 72%, 271/376, for the text-only group). The proportion of patients who actually received the influenza vaccine after the intervention also did not differ by messaging type (P=.07). The strongest predictor of both intention to receive and actual receipt of the influenza vaccine was prior influenza vaccination. Older age was also associated with a higher likelihood of the intention to receive (age 36-75 years relative to 18-35 years; P=.006) and actual receipt (age >75 years relative to 18-35 years; P=.05) of the influenza vaccine. ConclusionsThe proportion of patients receiving the influenza vaccine was high in both groups, but there was no difference in receipt of or in the intention to receive preventive health recommendations by type of messaging. Notably, a portion of patients in both groups had intended to be vaccinated but did not ultimately receive the vaccine. Further evaluation of patient-education strategies is warranted to improve preventive health uptake among patients with IBD. Trial RegistrationClinicalTrials.gov NCT05997537; https://clinicaltrials.gov/ct2/show/NCT05997537

Published
2023
Full Text
View/download PDF

3. Project PREVENT: A Randomized, Controlled Trial of Web-Based Video Education to Improve Uptake of Preventive Health Recommendations in Adults with Inflammatory Bowel Disease (Preprint)

Author

Millie D. Long, Welmoed K. van Deen, Laura Weisbein, Carine Khalil, Keren L. Appel, Xian Zhnag, Wenli Chen, Lori Zubrod, Robbie Maris, Afsoon Ghafari, Taylor Dupuy, Christina Y. Ha, Brennan M.R. Spiegel, Christopher V. Almario, and Gil Y. Melmed

Abstract

UNSTRUCTURED Background/Aims: Inflammatory bowel disease (IBD) patients are at increased risk of infections, bone fractures and skin cancers. We developed preventive health videos using a patient-centered approach, and tested their impact on preventive health uptake. Methods: Five animated videos explaining preventive health recommendations in IBD were iteratively developed with patient-centered focus groups and interviews. A randomized controlled trial was then conducted in an internet-based IBD cohort to test the impact of video vs. text-based educational interventions. The primary outcome was receipt of the influenza vaccine. Secondary outcomes included intent-to-receive other preventive health services. Results: Five animated videos were developed with patient input. A total of 1056 IBD patients were then randomized to receive the video (n=511) or text-only (n=545) interventions; 55% of the video group and 57% of the text-only group had received influenza vaccination in the prior year. Immediately following the intervention, 73% reported intent-to-receive vaccination, with no difference by type of intervention. The proportion of patients who actually received influenza vaccination following the intervention also did not differ by messaging type (p=0.07). The strongest predictor of both intent-to-receive and actual receipt of influenza vaccination was prior influenza vaccination. Older age was also associated with a higher likelihood of intent-to-receive (age 36-75 relative to 18-35 years; p=0.006) as well as actual receipt (age >75 relative to age 18-35 years; p=0.05) of the influenza vaccine. Conclusions: The proportion of patients receiving influenza vaccine was high in both groups, but there was no difference in receipt of, or in intention-to-receive preventive health recommendations by type of messaging. Notably, a portion of patients in both groups had intended to be vaccinated but did not ultimately receive vaccination. Further evaluation of patient-education strategies is warranted to improve preventive health uptake among patients with IBD.

Published
2022
Full Text
View/download PDF

4. S950 Symptomology Following SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease Relative to Healthcare Workers

Author

Angela Mujukian, Gregory J. Botwin, Rashmi Kumar, Brigid Boland, Michael Chiorean, Erica R. Cohen, David Fudman, Jason Hou, Caroline Hwang, Mark Lazarev, Donald F. Lum, Mark C. Mattar, Ryan McConnell, Arthur Ostrov, Nimisha Parekh, Douglas C. Wolf, Younis Ziad, Bradley Morganstern, Arash Horizon, Keren L. Appel, Swamy Venuturupalli, Daniel J. Wallace, Sarah Glover, Christina Ha, Gaurav Syal, Andrea Banty, Shervin Rabizadeh, Edward J. Feldman, Susie K. Lee, Theodore Stein, Nancy Sun, Min Wu, Joseph Ebinger, Susan Cheng, Gil Melmed, Dermot McGovern, and Jonathan Braun

Subjects
Vaccination, 2019-20 coronavirus outbreak, Hepatology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Gastroenterology, medicine, medicine.disease, business, Inflammatory bowel disease
Published
2021
Full Text
View/download PDF

5. Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Author

Andrea Banty, Edward J. Feldman, Laura E. Raffals, Stephan R. Targan, Jonathan Braun, Erica R. Cohen, Susie Lee, Dermot P.B. McGovern, Gregory J. Botwin, Valeriya Pozdnyakova, Jason K. Hou, Theodore Stein, Emebet Mengesha, Nimisha K. Parekh, Corey A. Siegel, Mark C. Mattar, Joseph E. Ebinger, Jane Figuereido, John Prostko, Edwin C. Frias, Donald Lum, Kimia Sobhani, Sarah Sheibani, Ann D. Flynn, Mark Metwally, Aline Charabaty, Gaurav Syal, James L. Stewart, Swapna Reddy, Mark Lazarev, Rashmi Kumar, Keren L. Appel, Ziad Younes, Caroline Hwang, Gil Y. Melmed, Arthur Ostrov, David Ziring, David I. Fudman, Philip Debbas, John F. Valentine, Michael V. Chiorean, Rebecca Fausel, Brigid S. Boland, Melissa Hampton, Douglas C. Wolf, Christina Ha, Susan Cheng, Arash Horizon, Eric A. Vasiliauskas, and Shervin Rabizadeh

Subjects
2019-20 coronavirus outbreak, Messenger RNA, COVID-19 Vaccines, Hepatology, Coronavirus disease 2019 (COVID-19), Ad26COVS1, business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, COVID-19, medicine.disease, Inflammatory Bowel Diseases, Virology, Inflammatory bowel disease, Article, Antibody response, Antibody Formation, Medicine, Humans, RNA, Viral, In patient, business
Published
2021

6. S741 Psychological Distress During a Global Pandemic: Prevalence and Risk Factors in a National Cohort of Inflammatory Bowel Disease (IBD) Patients

Author

Erica R. Cohen, Gregory J. Botwin, Gil Melmed, Dermot McGovern, Jonathan Braun, Brigid Boland, Michael Chiorean, David Fudman, Jason Hou, Caroline Hwang, Mark Lazarev, Donald F. Lum, null FACG, Mark C. Mattar, Ryan McConnell, Arthur Ostrov, Douglas C. Wolf, Ziad Younis, Bradley Morganstern, Arash Horizon, Keren L. Appel, Swamy Venuturupalli, Daniel J. Wallace, Sarah Glover, Christina Ha, Gaurav Syal, Andrea Banty, Shervin Rabizadeh, Edward J. Feldman, Susie K. Lee, Theodore Stein, Susan Cheng, Rashmi Kumar, and Nimisha Parekh

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Hepatology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, Psychological distress, medicine.disease, Inflammatory bowel disease, National cohort, Internal medicine, Pandemic, Medicine, business
Published
2021
Full Text
View/download PDF

7. S904 Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease After SARS-CoV-2 mRNA Vaccination

Author

Rashmi Kumar, Gregory J. Botwin, Arash Horizon, Keren L. Appel, Angela Mujukian, Brigid Boland, Michael Chiorean, Erica R. Cohen, David Fudman, Jason Hou, Caroline Hwang, Mark Lazarev, Donald F. Lum, null FACG, Mark C. Mattar, Ryan McConnell, Arthur Ostrov, Nimisha Parekh, Douglas C. Wolf, Ziad Younis, Bradley Morganstern, Swamy Venuturupalli, Daniel J. Wallace, Joseph Ebinger, Sarah Glover, Christina Ha, Gaurav Syal, Andrea Banty, Valeriya Pozdnyakova, Shervin Rabizadeh, Edward J. Feldman, Susie K. Lee, Theodore Stein, Susan Cheng, Jonathan Braun, Gil Melmed, and Dermot McGovern

Subjects
medicine.medical_specialty, Abdominal pain, Hepatology, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, Disease, medicine.disease, Ulcerative colitis, Inflammatory bowel disease, digestive system diseases, Vaccination, Diarrhea, Internal medicine, medicine, In patient, medicine.symptom, business
Abstract

Introduction: In the SARS-CoV2 mRNA vaccine trials, post-vaccination gastrointestinal (GI) symptoms were reported in 10-20% of participants. These symptoms could be perceived as inflammatory bowel disease (IBD) flare which could lead to patient anxiety, and unnecessary tests or treatment. We aimed to assess GI symptoms after SARS-CoV2 mRNA vaccination in patients with IBD relative to non-IBD healthcare workers (HCW). Methods: We assessed GI symptoms in adults with IBD and HCW at baseline and after each dose of a SARS-CoV-2 mRNA vaccine. We analyzed patient-reported IBD-specific disease activity (PRO2) after each dose (stool frequency (SF) and rectal bleeding for ulcerative colitis (UC), SF and abdominal pain for Crohn's disease (CD)). We also compared the frequency, severity, and duration of postvaccination GI symptoms in IBD patients compared to HCW. Severity was defined by impact on daily activities (mild, did not interfere;moderate, some interference;severe, prevented routine activity;extreme, required hospitalization). Severe and extreme were combined and designated as severe+. Duration was classified as 7 days. Results: Post-vaccination GI symptoms were assessed after dose 1 (D1) (1391 IBD, 933 HCW) and dose 2 (D2) (1271 IBD, 884 HCW) (Table). About 60% of IBD and>99% of HCW received the BNT162b vaccine (Pfizer);the remainder received mRNA-1273 (Moderna). New GI symptoms after D1 were more frequent among IBD than HCW (6.0% vs 2.9%, p=0.001) but not after D2 (12.1% vs 12.7%, p=NS). Relative to HCW, IBD patients reported more diarrhea (3.8% vs. 1% (p

Published
2021
Full Text
View/download PDF

8. S926 Effects of Immune Modifying Therapies on Antibody Responses Following SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease

Author

Gil Melmed, Gregory J. Botwin, Ziad Younis, Douglas C. Wolf, Michael Chiorean, Erica R. Cohen, Brigid Boland, Ann D. Flynn, David Fudman, Jason Hou, Mark Lazarev, Donald F. Lum, Mark C. Mattar, Ryan McConnell, Arthur Ostrov, Nimisha Parekh, Laura Raffals, Sarah Sheibani, Corey Siegel, John Valentine, Bradley Morganstern, Arash Horizon, Swamy Venuturupalli, Daniel J. Wallace, Sarah Glover, Adam C. Ehrlich, Christina Ha, Gaurav Syal, Rashmi Kumar, Keren L. Appel, Angela Mujukian, Shervin Rabizadeh, Edward J. Feldman, Theodore Stein, Susan Cheng, Joseph Ebinger, Kimia Sobhani, Jonathan Braun, and Dermot McGovern

Subjects
Messenger RNA, 2019-20 coronavirus outbreak, Hepatology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, medicine.disease, Inflammatory bowel disease, Vaccination, Antibody response, Immune system, Immunology, medicine, business
Published
2021
Full Text
View/download PDF

9. S824 Humoral Response to Ad26.COV2.S and SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Author

Valeriya Pozdnyakova, Gregory J. Botwin, Keren L. Appel, Rashmi Kumar, Nirupama Bonthala, Caroline Hwang, David Ziring, Melissa Hampton, Emebet Mengesha, Cindy D. Zamudio, Shane White, null CCRC, Philip Debbas, Diana Benliyan, Anzhelya Makaryan, Yin Li, Justina Ibrahim, Mary Hanna, Angela Mujukian, Susie K. Lee, Andrea Banty, Min Wu, Sandy Joung, Sarah Sternbach, Joseph Ebinger, Kimia Sobhani, Susan Cheng, Dermot McGovern, Jonathan Braun, and Gil Melmed

Subjects
2019-20 coronavirus outbreak, Messenger RNA, Hepatology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Gastroenterology, Medicine, In patient, business, medicine.disease, Virology, Inflammatory bowel disease
Published
2021
Full Text
View/download PDF

10. S742 A National Cohort of IBD Patients Exhibit Strong COVID-19 Safety Practice Beliefs

Author

Erica R. Cohen, Gregory J. Botwin, Brigid Boland, Michael Chiorean, David Fudman, Jason Hou, Caroline Hwang, Mark Lazarev, Donald F. Lum, Mark C. Mattar, Ryan McConnell, Arthur Ostrov, Douglas C. Wolf, Ziad Younis, Bradley Morganstern, Arash Horizon, Keren L. Appel, Rashmi Kumar, Swamy Venuturupalli, Daniel J. Wallace, Sarah Glover, Christina Ha, Gaurav Syal, Andrea Banty, Shervin Rabizadeh, Edward J. Feldman, Susie K. Lee, Theodore Stein, Susan Cheng, Gil Melmed, Dermot McGovern, Jonathan Braun, and Nimisha Parekh

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, Hepatology, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Family medicine, Gastroenterology, medicine, business, National cohort
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results